"Breakthrough Alzheimer's Drug Restores Patient's Quality of Life"

An Ohio grandmother, Joan Murtaugh, who participated in a clinical trial at the Cleveland Clinic for the new Alzheimer's drug Leqembi (lecanemab), has reported significant improvements in her memory and overall functionality. Developed by Biogen and Eisai, Leqembi is the first drug proven to delay the progression of Alzheimer's by targeting the underlying disease process. Another promising Alzheimer's medication, donanemab, is expected to be approved by the FDA this fall. These breakthrough drugs mark the beginning of a new era in Alzheimer's therapies, offering hope for patients and their families.